NDAORALTABLET
Approved
Jul 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SALURON (hydroflumethiazide) is an oral thiazide diuretic approved in 1959 for management of hypertension and edema. It reduces blood pressure and fluid retention by inhibiting sodium reabsorption in the distal convoluted tubule of the nephron. This legacy small-molecule diuretic represents foundational antihypertensive therapy.
LOE Approaching
Declining revenue trajectory with modest competitive pressure (30/100) signals a mature, stable-to-shrinking team focused on retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension
Started Mar 2013
0Hypertension
Career Relevance
SALURON offers minimal career growth potential as a legacy product approaching loss of exclusivity with zero linked job openings. Roles on this brand are primarily defensive, focused on maximizing remaining revenue, managing generic competition, and supporting existing patient populations rather than driving market expansion or innovation.
Brand Manager
Worked on SALURON at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.